Recruiting

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving therapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with congestive heart failure receiving therapy for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to congestive heart failure.

ClinicalTrials.gov IDNCT02610426

PhaseNot Applicable

Enrollment162

SponsorNational Cancer Institute (NCI)

AgeNot reported

SexALL

I'm interested View official listing

Conditions studied

Breast Carcinoma

About this study

Interventions

Other: Laboratory Biomarker Analysis — Correlative studies

Primary outcomes

Identification of rare coding variants of large effect that predict the risk of CHF (Baseline)

Eligibility information

Inclusion Criteria: * European American patients with DNA available * European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab * African American cases (based on a drop in left ventricular ejection fraction \[LVEF\] \< 50 or a drop from baseline \> 20 points) and African American controls

Study locations

Eastern Cooperative Oncology Group, Boston, Massachusetts 02215 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-14.